期刊文献+
共找到874篇文章
< 1 2 44 >
每页显示 20 50 100
Effects of antiplatelet drug combined with magnesium sulfate on platelet function and trophoblast apoptosis in patients with preeclampsia
1
作者 Wei-Dong Wang 《Journal of Hainan Medical University》 2018年第15期57-60,共4页
Objective: To investigate the effects of antiplatelet drug combined with magnesium sulfate on platelet function and trophoblast apoptosis in patients with preeclampsia. Methods: A total of 68 patients with preeclampsi... Objective: To investigate the effects of antiplatelet drug combined with magnesium sulfate on platelet function and trophoblast apoptosis in patients with preeclampsia. Methods: A total of 68 patients with preeclampsia who were treated in this hospital between September 2016 and September 2017 were chosen as the research subjects and divided into the control group (n=34) and the study group (n=34) by the random number table method. Control group received magnesium sulfate spasmolysis, and study group received low-dose aspirin combined with magnesium sulfate therapy. The differences in the levels of platelet function parameters as well as the expression levels of apoptosis-related genes and invasion-related genes in placental tissues were compared between the two groups of patients after treatment. Results:After treatment, the platelet function parameter PLT level in study group was higher than that in control group whereas MPV and PDW levels were lower than those in control group;pro-apoptosis genes Caspase-3, p53 and bax mRNA expression levels in placental tissues were lower than those of control group whereas anti-apoptosis gene bcl-2 mRNA expression level was higher than that of control group;pro-invasion genes MMP-2, MMP-9 and CXCL16 mRNA expression levels in placental tissues were higher than those of control group whereas anti-invasion genes RECK and DPPⅣ mRNA expression levels were lower than those of control group. Conclusion: Low-dose aspirin combined with magnesium sulfate treatment of patients with preeclampsia can effectively optimize the platelet function and inhibit the apoptosis of placental trophoblast cells and promote their invasion function. 展开更多
关键词 PREECLAMPSIA ANTIplatelet drug platelet function APOPTOSIS INVASION
下载PDF
Effect of Buyang Huanwu Decoction on Platelet Activating Factor Content in Arterial Blood Preand Post-Arterial Thrombosis in Rats 被引量:7
2
作者 张继平 李长龄 +1 位作者 郭欣欣 王桂玲 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2001年第4期299-302,共4页
To explore the effect of Buyang Huanwu Decoction (BHD) on platelet activating factor (PAF) content in arterial blood pre- and post-arterial thrombosis in rats, male Wistar rats were randomly divided into 3 groups, the... To explore the effect of Buyang Huanwu Decoction (BHD) on platelet activating factor (PAF) content in arterial blood pre- and post-arterial thrombosis in rats, male Wistar rats were randomly divided into 3 groups, the medicine group treated with BHD, the control group with dexamethasone liquid, and the blank group with distilled water. Oral administration was given for 14 consecutive days, once daily. Model of arterial thrombosis was established in the animals 2 hours after final medication, the blood content of PAF, dry weight (DW) and occlusion time (OT) of thrombus, and dry weight of thrombus/body weight (TW/BW) ratio were observed. Results indicated that BHD could markedly lower the arterial blood content of PAF after thrombosis, increase the OT of thrombus, reduce the dry weight of thrombus and the TW/BW ratio (P 展开更多
关键词 ANIMALS drugs Chinese Herbal MALE platelet Activating Factor RATS Rats Wistar THROMBOSIS
下载PDF
EFFECT OF 764-3 ON AGGREGATION AND CALCIUM MOVEMENTS IN AEQUORIN-LOADED HUMAN PLATELETS 被引量:1
3
作者 武怀珠 李家增 +2 位作者 彭林 滕彬 翟治清 《Chinese Medical Sciences Journal》 CAS CSCD 1996年第1期49-52,共4页
Washed human platelets were loaded with the Ca2+-sensitive photoprotein, aequorin. using hypoosmotic shock treatment-technique. Then aggregation and cytoplasmic ionized calcium concentration ( [Ca2+] i) changes in res... Washed human platelets were loaded with the Ca2+-sensitive photoprotein, aequorin. using hypoosmotic shock treatment-technique. Then aggregation and cytoplasmic ionized calcium concentration ( [Ca2+] i) changes in response to collagen or thrombin were measured simultaneously in the aequorin-loaded human platelets with a Platelet Ionized Calcium Aggregometer. 764-3. an active component isolated from the Chinese medicinal herb Salvia Miltiorrhiza Bge, inhibited platelet [Ca2+]i rise as well as aggregation evoked by collagen or thrombin in the presence of extracellular Ca2+. After the extracellular Ca2+. was removed by addition of EGTA, collagen or thrombin. causing no aggregation. still elicited platelet [Ca2+] i rise which reflected Ca2+ mobilization from intraplatelet stores. Under this condition, 764-3 could also suppress platelet [Ca2+] i rise. Analysis shows that 764-3 inhibrts platelet Ca2+ influx and Ca2+ mobilization with similar potency. which accounts for its suppression of platelet [Ca2+] i rise, and must contribute to its inhibition of platelet aggregation. 展开更多
关键词 antiplatelet drugs platelet aggregation platelet [Ca ̄(2+)] i
下载PDF
康替唑胺与利奈唑胺对70岁以上重症院内获得性肺炎患者的疗效比较 被引量:1
4
作者 那鹏 刘婷婷 +5 位作者 袁亚平 吴炯熇 王超 方向群 朱曼 李洪霞 《解放军医学院学报》 CAS 2024年第3期239-244,251,共7页
背景康替唑胺作为抗革兰阳性菌的新型药物,其疗效不劣于利奈唑胺,且不良反应的发生情况较利奈唑胺更低,但其在医院获得性肺炎(hospital acquired pneumonia,HAP)领域应用尚少。目的比较康替唑胺治疗利奈唑胺对高龄重症院内获得性肺炎(se... 背景康替唑胺作为抗革兰阳性菌的新型药物,其疗效不劣于利奈唑胺,且不良反应的发生情况较利奈唑胺更低,但其在医院获得性肺炎(hospital acquired pneumonia,HAP)领域应用尚少。目的比较康替唑胺治疗利奈唑胺对高龄重症院内获得性肺炎(severe hospital acquired pneumonia,SHAP)患者的疗效及不良反应。方法回顾性分析解放军总医院第二医学中心2021年1月1日—2023年2月15日发生SHAP、年龄≥70岁且在院内接受康替唑胺(800 mg,口服,1次/12 h)或利奈唑胺(600 mg,静滴或口服,1次/12 h)治疗患者的一般资料和临床资料,比较两组临床疗效及不良反应。结果共纳入358例患者。康替唑胺组111例,年龄(92.91±6.93)岁,男性占88.3%(98/111);利奈唑胺组247例,年龄(92.19±6.92)岁,男性占91.9%(227/247)。两组差异无统计学意义(P>0.05)。康替唑胺组与利奈唑胺的临床有效率分别为55.0%(61/111)和61.1%(151/247),差异无统计学意义(P>0.05)。对一般及临床基线指标进行倾向性评分匹配后,康替唑胺组与利奈唑胺组各36例患者,两组间临床有效率(61.1%vs 69.4%,P=0.458)、微生物清除率(22.2%vs 27.8%,P=0.296)差异均无统计学意义。康替唑胺组血小板下降的发生率显著低于利奈唑胺组(50.0%vs 80.6%,P=0.006);康替唑胺组和利奈唑胺组血红蛋白下降发生率分别为41.7%和61.1%,红细胞下降发生率分别为50.0%和61.1%,乳酸升高的发生率分别为44.1%和54.3%,乳酸酸中毒发生率分别为29.4%和34.3%,两组差异均无统计学意义(P>0.05)。结论康替唑胺治疗高龄SHAP的疗效与利奈唑胺相当,但其引起的血小板下降发生率显著低于利奈唑胺。 展开更多
关键词 康替唑胺 利奈唑胺 重症院内获得性肺炎 血小板下降 药物不良反应
下载PDF
靶向血小板的抗肿瘤药物研究进展
5
作者 周玥珂 钱程 +3 位作者 唐彧 韦忠红 陆茵 王爱云 《中国药理学通报》 CAS CSCD 北大核心 2024年第1期20-25,共6页
血小板长期以来一直被认为是止血和血栓形成的关键参与者;然而,越来越多的证据表明,它们也与癌症有关。临床前和临床研究表明,血小板可以通过血小板和癌细胞之间的各种串扰来促进肿瘤发生和转移。血小板在肿瘤发生的各个阶段,包括肿瘤... 血小板长期以来一直被认为是止血和血栓形成的关键参与者;然而,越来越多的证据表明,它们也与癌症有关。临床前和临床研究表明,血小板可以通过血小板和癌细胞之间的各种串扰来促进肿瘤发生和转移。血小板在肿瘤发生的各个阶段,包括肿瘤生长、肿瘤细胞外渗和转移中都发挥着积极的作用。此外,癌症患者的血小板增多与患者不良生存率相关。由于大量的微粒和外泌体,血小板还能够很好地协调局部和远处的肿瘤-宿主之间的相互作用。因此,以血小板为靶点的抗肿瘤药物具有很大的开发与应用前景。以下将对靶向血小板的抗肿瘤药物研究进展进行综述。 展开更多
关键词 血小板活化 血小板受体 肿瘤 血小板肿瘤细胞相互作用 抗肿瘤药 肿瘤发生和转移
下载PDF
西藏自治区人民医院实施国家重点监控药品干预成效分析
6
作者 巴桑拉姆 李杏翠 次仁德吉 《中国药事》 CAS 2024年第3期360-366,共7页
目的:评价西藏自治区人民医院对重点监控药品进行重点干预的成效,为优化重点监控药品干预策略、促进临床合理用药提供参考。方法:西藏自治区人民医院于2020年制订《西藏自治区人民医院重点监控药品管理规定》,建立《西藏自治区人民医院... 目的:评价西藏自治区人民医院对重点监控药品进行重点干预的成效,为优化重点监控药品干预策略、促进临床合理用药提供参考。方法:西藏自治区人民医院于2020年制订《西藏自治区人民医院重点监控药品管理规定》,建立《西藏自治区人民医院重点监控药品目录》,同时开展重点监控药品处方及医嘱专项点评、采取点评结果公示及绩效考核挂钩等目标性干预措施,对比西藏自治区人民医院2019年4月-2020年3月(干预前)与2020年4月-2021年3月(干预后第一年)及2021年4月-2022年3月(干预后第二年)重点监控药品临床使用数据变化,评价重点干预措施对该类药品的管理成效及临床使用的影响。结果:该院干预后第一年及第二年的重点监控药品销售金额分别为1427.01万元、1388.12万元,低于干预前的2004.29万元;干预后重点监控药品销售金额占药品总销售金额比例分别为8.33%、7.47%,低于干预前的10.11%。重点监控药品各品种的DDC普遍较高,患者的经济负担较重。结论:西藏自治区人民医院重点监控药品的干预取得了一定成效,但医院应在此基础上采取有力措施,提高重点监控药品合理使用,进一步减轻患者经济负担。 展开更多
关键词 重点监控药品 质控体系 合理用药 干预 成效分析
下载PDF
抗血栓药研究进展
7
作者 陶琦 冯基 +2 位作者 范丽萍 杨亚军 李剑勇 《中兽医医药杂志》 CAS 2024年第4期32-39,共8页
血栓形成在生理性止血中有着至关重要的作用,能够及时减少血液流失,但病理性血栓将严重危害机体的健康。血小板来源于巨核细胞胞质的分割断裂,其活化后具有多种功能,如黏附、释放和聚集等功能,并参与凝血反应。血栓的形成虽被众多因素影... 血栓形成在生理性止血中有着至关重要的作用,能够及时减少血液流失,但病理性血栓将严重危害机体的健康。血小板来源于巨核细胞胞质的分割断裂,其活化后具有多种功能,如黏附、释放和聚集等功能,并参与凝血反应。血栓的形成虽被众多因素影响,但其形成过程基本分为血小板的活化和凝血反应两步,其治疗药物主要分为抗血小板药物和抗凝血药物。目前,多种上市的抗血栓药物经相关受体、信号通路等各种途径抑制血栓的形成,有较好的临床效果,如阿司匹林、华法林等。但近年的研究与应用发现,多种抗血栓药物均存在一定的出血风险。近年来,随着宠物物质生活的不断提高,中老年伴侣动物的心血管疾病发病率呈逐年升高趋势。然而现阶段研究预防血栓形成的药物一般是用于人类,到目前为止,国内还没有宠物专用的预防血栓形成的药物上市。因此,开发新型有效的宠物专用预防血栓药物显得越发重要。本文总结现有抗血栓药的类型和作用机制,以期为宠物专用预防血栓药物的研发提供参考。 展开更多
关键词 血栓形成 血小板 凝血因子 凝血反应 抗血小板药物 抗凝血药物
下载PDF
富血小板血浆联合常规药物治疗雄激素性脱发有效性和安全性的meta分析
8
作者 田怡 李靖欢 +2 位作者 张广静 李孟 冯世军 《中国医疗美容》 2024年第4期110-114,共5页
目的系统评价富血小板血浆联合常规药物治疗雄激素性脱发患者的有效性和安全性。方法PubMed、Embase、Web of Science、Cochrane Library、Wiley online library等数据库,检索自建库至2024年2月10日发表的PRP联合常规药物治疗雄激素性... 目的系统评价富血小板血浆联合常规药物治疗雄激素性脱发患者的有效性和安全性。方法PubMed、Embase、Web of Science、Cochrane Library、Wiley online library等数据库,检索自建库至2024年2月10日发表的PRP联合常规药物治疗雄激素性脱发患者的英文文献。对纳入的文献进行数据提取,运用Cochrane系统评价员手册进行质量评价,应用相关统计软件进行分析。结果共纳入7项研究,合计396例患者。Meta分析结果显示:联合组在增加平均毛发密度和直径方面的疗效优于对照组(WMD=18.70,95%CI[8.00,29.40],P<0.001;WMD=11.60,95%CI[1.46,21.75],P=0.03)。在安全性上:联合PRP治疗时,患者发生不良反应的概率更低。且均未出现严重不良反应。结论联合富血小板血浆是治疗雄激素性脱发有效的治疗方法之一,但联合疗法的不良反应仍需进一步的研究和讨论。 展开更多
关键词 富血小板血浆 药物治疗 雄激素性脱发 META分析
下载PDF
应用失效模式与效应分析法提高药房盘点质量探索 被引量:1
9
作者 徐贞贞 田京辉 +3 位作者 张慧丽 汪荧辉 王清清 赵亮 《中国药事》 CAS 2024年第2期229-236,共8页
目的:优化现代化门诊药房药品盘点过程以提升盘点质量。方法:通过文献检索、头脑风暴等方法绘制药品盘点流程图并收集每个子流程的潜在失效模式及失效原因,应用失效模式与效应分析法(Failure Mode and Effect Analysis,FMEA)对各失效模... 目的:优化现代化门诊药房药品盘点过程以提升盘点质量。方法:通过文献检索、头脑风暴等方法绘制药品盘点流程图并收集每个子流程的潜在失效模式及失效原因,应用失效模式与效应分析法(Failure Mode and Effect Analysis,FMEA)对各失效模式发生的可能性、严重性和可侦测度进行评分及风险优先值(RPN)计算,量化并确定高风险失效模式,制定改进措施并实施,分析改善效果。结果:确定了盘点的3个主流程和12个子流程,以及各子流程相关的21项失效模式和38项失效原因,高风险因素共15项,制定针对性改进措施28项。干预改进后,各高风险失效模式RPN值均显著降低,其中最高的4项由392、288、280、280分别降至42、48、56、63,均处于相对低风险区域;干预管理前后复盘相符率由82.4%上涨至96.2%,盘存时长由180.2 min降至155.3 min。结论:FMEA法在药品盘点过程存在问题分析改进中的价值是肯定的,制定的各项改进措施,尤其是针对现代化药房自动化设备盘存模块的相关措施,以及低代码平台在智能化盘点中的应用等对于盘点质量的提升作用非常显著,值得借鉴并推广运用来提升药品经济和质量管理。 展开更多
关键词 失效模式与效应分析 现代化药房 药品盘点 低代码平台
下载PDF
血小板药物递送系统的研究进展
10
作者 贾翠萍 张媛 邓伟豪 《广州医药》 2024年第6期577-584,共8页
药物递送系统对于各类疾病意义非凡,但传统药物载体面临细胞毒性强、组织相容性低、半衰期短和靶向性弱等诸多挑战。血小板及其相关衍生物作为新型药物载体具有更为显著的优势。由于血小板自身的生理特点,以及在肿瘤、心血管疾病、血栓... 药物递送系统对于各类疾病意义非凡,但传统药物载体面临细胞毒性强、组织相容性低、半衰期短和靶向性弱等诸多挑战。血小板及其相关衍生物作为新型药物载体具有更为显著的优势。由于血小板自身的生理特点,以及在肿瘤、心血管疾病、血栓性疾病、感染等多种疾病中发挥的病理生理作用,血小板能够弥补传统药物载体的缺陷,具有极大的临床转化意义。该文总结了血小板相关药物递送系统目前的研究进展,以期为新型药物载体研究提供参考。 展开更多
关键词 血小板 仿生纳米颗粒 血小板衍生物 药物递送系统
下载PDF
1例泛耐药肺炎克雷伯菌尿源性脓毒症伴血小板减少的给药策略分析
11
作者 杨娟艳 高岸 徐红冰 《药学与临床研究》 2024年第2期169-171,共3页
临床药师对1例泛耐药肺炎克雷伯菌尿源性脓毒症伴血小板减少患者进行用药干预,分析替加环素联合黏菌素治疗效果不佳及血小板减少的原因,推荐头孢他啶阿维巴坦单药治疗产肺炎克雷伯菌(KPC)碳青霉烯酶类耐药肺炎克雷伯菌(CRKP)的重症感染... 临床药师对1例泛耐药肺炎克雷伯菌尿源性脓毒症伴血小板减少患者进行用药干预,分析替加环素联合黏菌素治疗效果不佳及血小板减少的原因,推荐头孢他啶阿维巴坦单药治疗产肺炎克雷伯菌(KPC)碳青霉烯酶类耐药肺炎克雷伯菌(CRKP)的重症感染,基于患者感染部位、病原菌酶型等,制定抗感染治疗方案后,患者感染指标和血小板逐渐恢复至正常范围,病情好转。 展开更多
关键词 泛耐药肺炎克雷伯菌 尿源性脓毒症 头孢他啶/阿维巴坦 血小板减少
下载PDF
替罗非班对进展性脑梗死患者血小板活性的影响及应用效果分析
12
作者 王燕 张桂月 陈翔 《国际医药卫生导报》 2024年第2期244-248,共5页
目的观察替罗非班对进展性脑梗死(progressive cerebral infarction,PCI)患者血小板活性的影响及临床应用效果。方法本研究为随机对照试验,前瞻性选取2021年1月至2023年3月南阳医学高等专科学校附属中医院收治的106例PCI患者作为研究对... 目的观察替罗非班对进展性脑梗死(progressive cerebral infarction,PCI)患者血小板活性的影响及临床应用效果。方法本研究为随机对照试验,前瞻性选取2021年1月至2023年3月南阳医学高等专科学校附属中医院收治的106例PCI患者作为研究对象,采用随机数字表法分为常规组和试验组,每组53例。常规组男30例、女23例,年龄(60.11±5.27)岁,予以常规药物治疗;试验组男31例、女22例,年龄(61.25±5.33)岁,采用替罗非班配合治疗。对比两组患者治疗前后血小板功能、炎症反应及神经功能改善情况,评估两组用药安全性。采用t检验、χ^(2)检验。结果治疗前,两组患者血小板活性、血小板功能、炎症指标、神经功能比较,差异均无统计学意义(均P>0.05)。治疗后,试验组β-血小板球蛋白(β-TG)、颗粒膜蛋白CD62P、CD63、血小板聚集率(PAgT)、血小板黏附率(PAdT)、白细胞介素-6(IL-6)、IL-8、C-反应蛋白(CRP)均低于常规组[(15.44±5.16)μg/L比(18.25±5.27)μg/L、(55.25±10.47)%比(61.45±10.46)%、(10.33±3.41)%比(12.28±3.16)%、(35.22±10.17)%比(42.11±10.48)%、(28.33±5.14)%比(31.45±5.16)%、(60.44±10.28)ng/L比(67.62±10.35)ng/L、(10.15±3.22)ng/L比(12.37±3.19)ng/L、(7.66±2.11)mg/L比(8.82±2.14)mg/L],差异均有统计学意义(t=2.774、3.050、3.054、3.435、3.119、3.583、3.566、2.810,均P<0.05)。治疗3 d、7 d、14 d后,试验组美国国立卫生研究院卒中量表(NIHSS)评分均低于常规组[(30.25±5.14)分比(33.47±5.26)分、(24.33±5.18)分比(27.85±5.61)分、(20.12±5.41)分比(23.36±5.41)分],差异均有统计学意义(t=3.188、3.356、3.083,均P<0.05)。治疗后,两组患者药物相关不良反应发生率比较,差异无统计学意义(P>0.05)。结论替罗非班能有效抑制PCI患者血小板活性,对改善血小板功能、减轻炎症反应并改善神经功能均有积极意义,联合应用此药未明显增加药物不良反应发生风险,安全性较高。 展开更多
关键词 替罗非班 进展性脑梗死 炎症反应 血小板活性 用药安全性
下载PDF
Targeted thrombolysis strategies for neuroprotective effect 被引量:2
13
作者 Junping Zhang Guoxing Ma +4 位作者 Zhimin Lv Yu Zhou Chunguang Wen Yaqing Wu Ruian Xu 《Neural Regeneration Research》 SCIE CAS CSCD 2014年第13期1316-1322,共7页
Stroke is usually treated by systemic thrombolytic therapy if the patient presents within an appropriate time window. There is also widespread interest in the development of thrombolytic agents that can be used in cas... Stroke is usually treated by systemic thrombolytic therapy if the patient presents within an appropriate time window. There is also widespread interest in the development of thrombolytic agents that can be used in cases of delayed presentation. Current agents that can be used in cases of delayed presentation of nerve damage by thrombus. Current systemic thrombolytic therapy is associated with adverse effects such as fibrinogenolysis and bleeding. In an attempt to increase the efficacy, safety, and specificity of thrombolytic therapy, a number of targeted thrombolytic agents have been studied in recent years. This review focuses on the concepts underlying targeted thrombolytic therapy and describes recent drug developments in this field. 展开更多
关键词 nerve regeneration review thrombolytic agent fibrinolytic system stroke cerebrovasculardisease neuroprotective drug fibrinolytic mechanism fbrin targeting platelet targeting red bloodcell targeting cerebral hemorrhage NSFC grant neural regeneration
下载PDF
The Pattern of Eosinophil Count among Nigerians with Frequent Use of the Commonly Available Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 被引量:1
14
作者 P. K. Uduagbamen A. T. Oyelese +4 位作者 A. O. Adebola Yusuf O. F. Salami C. M. Nwinee M. I. Ogunmola O. Ehioghae 《International Journal of Clinical Medicine》 2020年第10期605-617,共13页
<strong>Introduction: </strong>Non-steroidal anti-inflammatory drugs (NSAIDs) use is very common. NSAIDs use could be associated with elevated eosinophil count which could be a class effect or patient-rela... <strong>Introduction: </strong>Non-steroidal anti-inflammatory drugs (NSAIDs) use is very common. NSAIDs use could be associated with elevated eosinophil count which could be a class effect or patient-related. Inflammation could be the link between NSAIDs use and eosinophilia. <strong>Aims: </strong>To compare the pattern of eosinophil count in the peripheral blood of frequent users of NSAIDs and healthy controls. <strong>Methodology: </strong>Two hundred (one hundred frequent users of NSAIDs and 100 healthy controls) participants who had no known risk factor for kidney disease and had given informed consent were recruited. Blood was taken to determine the white cell count and differentials, serum electrolyte and creatinine, and random blood sugar. <strong>Results:</strong> The mean age of NSAIDs users was not significantly different from controls, P = 0.3. The mean eosinophil count was higher in males than females. The incidence of eosinophilia in NSAIDs users was 4%. The mean Eosinophil count of NSAIDs users was insignificantly higher than controls, 164.3 ± 51 6 vs 135. 6 ± 53.4, P = 0.4. The mean platelet count of NSAIDs users was significantly higher compared to controls, P = 0.04. The mean hematocrit of NSAIDs users was significantly lower than the controls, P = 0.02. Propionic acid derivatives were associated with the highest eosinophil count. Eosinophil count was positively related to age and serum creatinine and inversely related to blood glucose, hematocrit and glomerular filtration rate.<strong> Conclusion: </strong>The incidence of eosinophilia was 4%. The eosinophil count was higher in frequent NSAIDs users than occasional and non-users, in males than females and with use propionic acid derivatives compared to other NSAIDs. The Eosinophil count was positively related to age and platelet count. Being commoner in inflammatory states, the tissue destruction associated with elevated EC can be avoided by the prevention and prompt treatment of inflammatory conditions. 展开更多
关键词 EOSINOPHILIA Kidney Function Non-Steroidal Anti-Inflammatory drugs HEMATOCRIT platelet Count Propionic Acid
下载PDF
Organ transplantation and drug eluting stents:Perioperative challenges 被引量:1
15
作者 Aparna Dalal 《World Journal of Transplantation》 2016年第4期620-631,共12页
Patients listed for organ transplant frequently have severe coronary artery disease(CAD), which may be treated with drug eluting stents(DES). Everolimus and zotarolimus eluting stents are commonly used. Newer generati... Patients listed for organ transplant frequently have severe coronary artery disease(CAD), which may be treated with drug eluting stents(DES). Everolimus and zotarolimus eluting stents are commonly used. Newer generation biolimus and novolimus eluting biodegradable stents are becoming increasingly popular. Patients undergoing transplant surgery soon after the placement of DES are at increased risk of stent thrombosis(ST) in the perioperative period. Dual antiplatelet therapy(DAPT) with aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel and ticagrelor is instated post stenting to decrease the incident of ST. Cangrelor has recently been approved by Food and Drug Administration and can be used as a bridging antiplatelet drug. The risk of ischemia vs bleeding must be considered when discontinuing or continuing DAPT for surgery. Though living donor transplant surgery is an elective procedure and can be optimally timed, cadaveric organ availability is unpredictable, therefore, discontinuation of antiplatelet medication cannot be optimally timed. The type of stent and timing of transplant surgery can be of utmost importance. Many platelet function point of care tests such as Light Transmittance Aggregrometry, Thromboelastography Platelet Mapping, VerifyN ow, Multiple Electrode Aggregrometry are used to assess bleeding risk and guide perioperative platelet transfusion. Response to allogenic platelet transfusion to control severe intraoperative bleeding may differ with the antiplatelet drug. In stent thrombosis is an emergency where management with either a drug eluting balloon or a DES has shown superior outcomes. Post-transplant complications often involved stenosis of an important vessel that may need revascularization. DES are now used for endovascular interventions for transplant orthotropic heart CAD, hepatic artery stenosis post liver transplantation, transplant renal artery stenosis following kidney transplantation, etc. Several antiproliferative drugs used in the DES are inhibitors of mammalian target of rapamycin. Thus they are used for post-transplant immunosuppression to prevent acute rejection in recipients with heart, liver, lung and kidney transplantation. This article describes in detail the various perioperative challenges encountered in organ transplantation surgery and patients with drug eluting stents. 展开更多
关键词 drug eluting STENTS CANGRELOR Stent thrombosis Organ transplant ANTIplatelet medication platelet function assays Mammalian target of rapamycin inhibitors POST-TRANSPLANT immunosuppression POST-TRANSPLANT ENDOVASCULAR inhibition Ticagrelor Thromboelastograms platelet mapping Novolimus Biolimus A9
下载PDF
Platelet-derived growth factor signaling in human malignancies 被引量:1
16
作者 Kun-Wei Liu Bo Hu Shi-Yuan Cheng 《Chinese Journal of Cancer》 SCIE CAS CSCD 北大核心 2011年第9期581-584,共4页
Platelet-derived growth factors (PDGFs) and their receptors were identified and purified decades ago. PDGFs are important during normal development and in human cancers. In particular, autocrine PDGF signaling has bee... Platelet-derived growth factors (PDGFs) and their receptors were identified and purified decades ago. PDGFs are important during normal development and in human cancers. In particular, autocrine PDGF signaling has been implicated in various types of malignancies such as gliomas and leukemia. In contrast, paracrine signaling was found in cancers that originate from epithelial cells, where it may be involved in stromal cell recruitment, metastasis, and epithelial-mesenchymal transition. This editorial briefly discusses autocrine and paracrine PDGF signaling and their roles in human cancers, and introduces a series of review articles in this issue that address the possible roles of PDGFs in various processes involved in different types of cancers. 展开更多
关键词 生长因子 恶性肿瘤 血小板 信号 人类 衍生 PDGF 上皮细胞
下载PDF
Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through plateletcycloxygenase inhibition
17
作者 Jan Jacques Michiels 《World Journal of Hematology》 2017年第3期32-54,共23页
Hypersensitive(sticky) platelets in JAK2-mutated essential thrombocythemia(ET) and polycythemia vera(PV) with thrombocythemia spontaneously activate at high shear in arterioles, secrete their inflammatory prostaglandi... Hypersensitive(sticky) platelets in JAK2-mutated essential thrombocythemia(ET) and polycythemia vera(PV) with thrombocythemia spontaneously activate at high shear in arterioles, secrete their inflammatory prostaglandin endoperoxides and induce plateletmediated arteriolar fibromuscular intimal proliferation. Constitutively activated JAK2 mutated hypersensitive(sticky) platelets spontaneously aggregate at high shear in the endarteriolar circulation as the cause of aspirin responsive erythromelalgia and platelet arterial thrombophilia in JAK2-mutated thrombocythemia patients. Increased production of prostglandin endoperoxides E2 and thromboxane A2 released by activated sticky platelets in arterioles account for redness warmth and swelling of erythromelalgia and platelet derived growth factor can readily explain the arteriolar fibromuscular intimal proliferation. Von Willebrand factor(VWF) platelet rich occlusive thrombi in arterioles are the underlying pathobiology of erythromelalgic acrocyanosis, migraine-like transient cerebral attacks(MIAs), acute coronary syndromes and abdominal microvscular ischemic events. Irreversible platelet cyco-oxygenase inhibition by aspirin cures the erythromelalgia, MIAs and microvascular events, corrects shortened platelet survival to normal, and returns increased plasma levels of betaTG, platelet factor 4, thrombomoduline and urinary thromboxane B2 excretion to normal in symptomatic JAK2-thrombocythemia patients. In vivo activation of sticky platelets and VWF-platelet aggregates account for endothelial cell activation to secrete thrombomoduline and sVCAM followed by occlusion of arterioles by VWF-rich platelet thrombi in patients with erythromelalgic thrombotic thrombocythemia(ETT) in ET and PV patients. ETT is complicated by spontaneous hemorrhagic thrombocythemia(HT) or paradoxical ETT/HT due to acquired von Willebrand disease type 2A at platelet counts above 1000 × 10~9/L and disappears by cytoreduction of platelets to normal(< 400 × 10~9/L). 展开更多
关键词 ASPIRIN Wonder drug ERYTHROMELALGIA Cerebral vascular disturbances platelet CYCLOOXYGENASE MIGRAINE
下载PDF
In-Stent Thrombosis after Antiplatelet Therapy Conversion while Awaiting Coronary Bypass
18
作者 Nathan Burke Tawanna Charlton +1 位作者 Hussam Hawamdeh Ki Park 《Cardiovascular Innovations and Applications》 2020年第4期139-143,共5页
In-stent thrombosis(IST)is a rare yet dangerous complication that may occur despite optimized coronary intervention in the cardiac catheterization laboratory.This is a case of an 81-year-old man who presented with ST-... In-stent thrombosis(IST)is a rare yet dangerous complication that may occur despite optimized coronary intervention in the cardiac catheterization laboratory.This is a case of an 81-year-old man who presented with ST-elevation myocardial infarction.Right coronary artery(RCA)occlusion was suspected.RCA angiography and percutaneous coronary intervention were performed.Complicated left coronary artery disease was subsequently discovered.Per cardiothoracic surgeon request,the patient was transitioned from ticagrelor to clopidogrel therapy in preparation for coronary artery bypass grafting.The patient experienced IST the day before surgery while receiving clopidogrel.We examine this case,which highlights the complexity of antiplatelet therapy choice and the role of genetic testing in evaluation of IST risk. 展开更多
关键词 Acute myocardial infarction/ST-elevation myocardial infarction antiplatelet therapy GENETICS platelet biology drug-eluting stent drugs/pharmacotherapy
下载PDF
原研和仿制替格瑞洛在经皮冠状动脉介入术后应用的相关对比研究 被引量:1
19
作者 周洋 张泽华 +4 位作者 彭文星 张芸楠 韩嘉伦 石秀锦 林阳 《中国医药》 2023年第10期1441-1445,共5页
目的通过对比原研与仿制替格瑞洛在经皮冠状动脉介入(PCI)术后应用的有效性、安全性与经济性,为临床决策与政策实施提供参考。方法回顾性收集首都医科大学附属北京安贞医院2019年1月至2021年12月诊断为急性冠状动脉综合征(ACS)并接受了... 目的通过对比原研与仿制替格瑞洛在经皮冠状动脉介入(PCI)术后应用的有效性、安全性与经济性,为临床决策与政策实施提供参考。方法回顾性收集首都医科大学附属北京安贞医院2019年1月至2021年12月诊断为急性冠状动脉综合征(ACS)并接受了PCI手术治疗的患者的相关就诊与随访数据,根据患者使用的替格瑞洛品种分为原研药组与仿制药组。比较2组有效性(血小板最大聚集率及其达标率)、安全性(出血事件)和经济性(用药频度、日均费用)相关指标。结果共纳入2685例患者,原研药组1838例,仿制药组847例。倾向性评分匹配后2组各841例。2组血小板最大聚集率、血小板最大聚集率达标率比较差异均无统计学意义(均P>0.05)。原研药组共9例患者出现便潜血事件,发生率为1.1%(9/841),仿制药组共10例患者出现便潜血事件,发生率为1.2%(10/841)。带量采购政策实施后替格瑞洛仿制药用药频度明显高于原研药且日均费用有较大下降。结论仿制替格瑞洛与原研替格瑞洛的有效性与安全性无显著差异,但具有更好的经济性。 展开更多
关键词 急性冠状动脉综合征 替格瑞洛 仿制药 血小板最大聚集率
下载PDF
新生血管性年龄相关性黄斑变性治疗的研究进展
20
作者 邱梅园 吴沛霖 《医学综述》 CAS 2023年第18期3632-3637,共6页
年龄相关性黄斑变性(AMD)是一种中心性视力不可逆性丧失的疾病。血管内皮生长因子(VEGF)是新生血管性AMD(nAMD)发病的重要因素,目前抗VEGF治疗仍是临床一线治疗方案。尽管抗VEGF治疗在一定程度上能够减缓疾病进展和视力丧失,但患者仍需... 年龄相关性黄斑变性(AMD)是一种中心性视力不可逆性丧失的疾病。血管内皮生长因子(VEGF)是新生血管性AMD(nAMD)发病的重要因素,目前抗VEGF治疗仍是临床一线治疗方案。尽管抗VEGF治疗在一定程度上能够减缓疾病进展和视力丧失,但患者仍需要频繁玻璃体腔注射,长期治疗效果并不理想。因此,为改善疗效,针对传统抗VEGF治疗的替代方案相继出现,如新型抗VEGF药物、基因治疗、血小板衍生生长因子抑制剂、血管生成素/Tie信号通路药物、新型药物缓释系统等。随着研究的深入,相信会有更多的延长型及多靶点药物可供nAMD患者选择。 展开更多
关键词 新生血管性年龄相关性黄斑变性 血管内皮生长因子 血小板衍生生长因子 血管生成素/Tie信号通路 新型药物缓释系统
下载PDF
上一页 1 2 44 下一页 到第
使用帮助 返回顶部